Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease. European Commission decision anticipated in beginning of May.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PLX:
